<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056743</url>
  </required_header>
  <id_info>
    <org_study_id>CUH_2012_RG</org_study_id>
    <nct_id>NCT02056743</nct_id>
  </id_info>
  <brief_title>Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers</brief_title>
  <official_title>Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the possibility of drug interactions before and
      after taking red ginseng or fermented-red ginseng by estimating metabolic rate of indicator
      drugs for cytochrome P450 and P-glycoprotein.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve (AUClast)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve (AUCinf)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First time to reach Cmax (Tmax)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AUClast ratio</measure>
    <time_frame>Up to last analysis time of each drug and concentration ratio of drug/metabolite in plasma and urine samples of various sampling time</time_frame>
    <description>CYP cocktail: 0, 0.25, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h / Fexofenadine: 0, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 h / Urine for Losartan and Dextromethorphan: 0-4, 4-8, 8-12 h</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fermented-red ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYP cocktail</intervention_name>
    <description>Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.</description>
    <arm_group_label>Fermented-red ginseng</arm_group_label>
    <arm_group_label>Red ginseng</arm_group_label>
    <other_name>Caffeine 200mg</other_name>
    <other_name>Losartan 50mg</other_name>
    <other_name>Omeprazole 20mg</other_name>
    <other_name>Dextromethorphan 30mg</other_name>
    <other_name>Midazolam 7.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine 30mg</intervention_name>
    <description>Each group administered Fexofenadine 30mg under fasting conditions.</description>
    <arm_group_label>Fermented-red ginseng</arm_group_label>
    <arm_group_label>Red ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Red ginseng</intervention_name>
    <description>During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.</description>
    <arm_group_label>Red ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented-red ginseng</intervention_name>
    <description>During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.</description>
    <arm_group_label>Fermented-red ginseng</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 20 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt; 45 kg.

          -  An informed consent document signed and dated by the subject.

          -  Subject who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Any condition possibly affecting drug absorption (e.g. gastrectomy)

          -  History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 150 mL of
             wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of Screening

          -  Participating in a bioequivalence study or other clinical study within 3 months
             preceding the first dose of study medication

          -  Screening sitting blood pressure &gt; 160 mm Hg (systolic) or &gt;90 mm Hg (diastolic),
             following at least 5 minutes of rest.

          -  History of significant alcohol abuse or drug abuse within one year prior to the
             Screening

          -  Use of any drugs known to significantly induce or inhibit drug-metabolizing enzymes
             within 30 days prior to dosing

          -  Smoking over 20 cigarettes per day

          -  Use of prescription or nonprescription drugs and dietary supplements within 10 days or
             5 half-lives (whichever is longer) prior to the first dose of study medication.

          -  Blood donation within 2 months prior to dosing, or plasma donation within 2 weeks
             prior to dosing

          -  Unwilling or unable to comply with the Lifestyle guidelines described in this protocol

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study

          -  Subjects who are hypersensitive to investigational drugs or related compounds

          -  Subjects with hereditary disease of galactose intolerance, Lapp lactase deficiency or
             gulucose-galactose malabsorption

          -  Subjects who are decided incongruity to participated in this study by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dal-Sik Kim, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min-Gul Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center of Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Dal-Sik Kim</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

